Serum Institute of India: Covishield (Oxford/ AstraZeneca formulation)
Vaccine Type: Non Replicating Viral Vector
Vaccine Trial & Approval Tracker
This vaccine is approved.
Phase 1: 0 Trials
There are no trials for this phase.
Phase 2: 2 Trials
Phase 3: 4 Trials
-
CTRI/2022/04/042017
India -
CTRI/2022/04/041792
India -
NCT05567471
India -
CTRI/2020/08/027170
India
Approvals
Africa Regulatory Taskforce Endorsed
Caribbean Regulatory System Emergency Use Recommendation
49 Countries
- Afghanistan
- Antigua and Barbuda
- Argentina
- Bahamas
- Bahrain
- Bangladesh
- Barbados
- Belize
- Bhutan
- Bolivia (Plurinational State of)
- Botswana
- Brazil
- Cabo Verde
- Canada
- Côte d'Ivoire
- Dominica
- Egypt
- Ethiopia
- Ghana
- Grenada
- Guyana
- Honduras
- Hungary
- India
- Jamaica
- Lebanon
- Madagascar
- Maldives
- Morocco
- Myanmar
- Namibia
- Nepal
- Nicaragua
- Nigeria
- Republic of Moldova
- Saint Kitts and Nevis
- Saint Lucia
- Saint Vincent and the Grenadines
- Seychelles
- Solomon Islands
- Somalia
- South Africa
- Sri Lanka
- Suriname
- Syrian Arab Republic
- Togo
- Tonga
- Trinidad and Tobago
- Ukraine
This vaccine is the same formulation as the Oxford/AstraZeneca vaccine (AZD1222)
Registered Trials
-
CTRI/2022/04/042017
Phase 3India
Total Enrollment: 372
Official Trial Registration:
-
CTRI/2022/04/041792
Phase 3India
Total Enrollment: 580
Official Trial Registration:
-
NCT05567471
Phase 3India
Total Enrollment: 875
Official Trial Registration:
-
CTRI/2020/08/027170
Phase 2/3India
Total Enrollment: 1,600
Official Trial Registration:
-
NCT05542693
Phase 2Total Enrollment: 300
Official Trial Registration: